Ivuxolimab Biosimilar – Anti-TNFRSF4, CD134 mAb – Research Grade

Description of Ivuxolimab Biosimilar - Anti-TNFRSF4, CD134 mAb - Research Grade

Introduction

Ivuxolimab Biosimilar, also known as Anti-TNFRSF4 or CD134 monoclonal antibody, is a research-grade antibody that targets the TNFRSF4 protein. This protein is also known as CD134 and is a member of the tumor necrosis factor receptor superfamily. Ivuxolimab Biosimilar is a novel therapeutic agent that shows promising potential in the treatment of various autoimmune and inflammatory diseases.

Structure

Ivuxolimab Biosimilar is a monoclonal antibody that specifically binds to the extracellular domain of the TNFRSF4 protein. It is a fully humanized IgG1 antibody with a molecular weight of approximately 150 kDa. The antibody is composed of two heavy chains and two light chains, each containing variable and constant regions. The variable regions of the antibody are responsible for recognizing and binding to the target protein, while the constant regions play a role in effector functions such as complement activation and antibody-dependent cell-mediated cytotoxicity.

Activity

The main activity of Ivuxolimab Biosimilar is its ability to block the interaction between TNFRSF4 and its ligand, OX40L. This interaction is crucial for the activation and proliferation of T cells, which play a key role in the pathogenesis of autoimmune and inflammatory diseases. By inhibiting this interaction, Ivuxolimab Biosimilar can suppress the immune response and reduce inflammation.

In addition, Ivuxolimab Biosimilar has been shown to induce regulatory T cells (Tregs), which are a type of immune cell that helps maintain immune tolerance and prevent autoimmune reactions. This mechanism of action makes Ivuxolimab Biosimilar a promising therapeutic option for diseases characterized by dysregulated immune responses, such as rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease.

Application

Ivuxolimab Biosimilar is currently being investigated for its potential use in the treatment of various autoimmune and inflammatory diseases. In preclinical studies, the antibody has shown efficacy in animal models of rheumatoid arthritis, multiple sclerosis, and lupus. These promising results have led to the initiation of clinical trials to evaluate the safety and efficacy of Ivuxolimab Biosimilar in humans.

One of the key advantages of Ivuxolimab Biosimilar is its specificity for TNFRSF4, which minimizes the risk of off-target effects and reduces the likelihood of adverse events. This makes it a potentially safer alternative to other immunosuppressive therapies currently available. Moreover, as a biosimilar, Ivuxolimab Biosimilar has the advantage of being more cost-effective compared to the original biologic drug, making it more accessible to patients.

Conclusion

In summary, Ivuxolimab Biosimilar is a promising therapeutic option for the treatment of autoimmune and inflammatory diseases. Its specific binding to TNFRSF4 and ability to induce Tregs make it a unique and potentially safer alternative to other immunosuppressive therapies. With ongoing clinical trials, Ivuxolimab Biosimilar has the potential to provide effective and affordable treatment options for patients suffering from these debilitating diseases.